key: cord-0786087-sceioxhq authors: Ricardo, Jose W.; Lipner, Shari R. title: Recommendations for Treatment of Nail Lichen Planus During the COVID‐19 Pandemic date: 2020-05-10 journal: Dermatol Ther DOI: 10.1111/dth.13551 sha: d3abe6ed31926104e65ba06d0b7b84fdc9887e0a doc_id: 786087 cord_uid: sceioxhq nan Dermatologists are facing unprecedented challenges due to SARS-CoV-2 in caring for their patients. Treatment algorithms utilized prior to the coronavirus disease 2019 pandemic are no longer applicable. 1 Nail lichen planus (NLP) is a true nail emergency, sometimes with an aggressive course, resulting in scarring, permanent nail loss, and significant impact on daily activities. 2 Treatment of NLP is difficult, and topicals are generally not preferred due to poor nail plate penetration and compliance. 3 Thus, intralesional and systemic therapies are mainstays of NLP treatment. Immunosuppressants play key roles in NLP treatment; however, their use may be a COVID-19-related mortality risk factor. 4 Therefore, we analyzed adverse event data in NLP patients receiving intralesional or systemic therapies, and provide therapeutic recommendations. Data on the adverse events with treatment of NLP is displayed in Table 1 . There were no reported infections in any of the studies. Triamcinolone acetonide (TAC) is considered firstline treatment for NLP. 3 The intralesional route is recommended in the absence of nail bed disease. 3 Intramuscular TAC is considered as an adjunct to intralesional administration for severe disease, particularly if >3 nails are affected; for nail bed lichen planus features, 5 intramuscular administration is favored. 3 Intralesional administration-related side effects are mild, including nail plate atrophy, subungual hematoma and transient digit numbness 3 ; the This article is protected by copyright. All rights reserved. risk of systemic toxicity is negligible. Although intramuscular TAC and prednisone-related infections have not been reported in NLP patients (Table 1) , studies are small and because they are both immunosuppressants, there are at least theoretical increased infection risks. Since intralesional/intramuscular TAC administration requires an in-person visit, these injections should be discontinued during the pandemic. Superpotent topical steroids under occlusion or oral non-immunosuppressants are preferred. An in-office visit for intralesional/intramuscular injections can be considered on a case-by-case basis if NLP is progressive despite use of alternative topical or systemic treatments. Retinoids are considered second-line treatment for NLP. 3 Azathioprine, cyclosporine and mycophenolate mofetil are third-line NLP treatments. 3 They are known to cause immunosuppression. However, their effect on susceptibility to and increased severity of COVID-19 infection is largely unknown. Treating physicians may consider tapering to the lowest effective dose during the pandemic. For patients positive/symptomatic for COVID-19, these immunosuppressants should be discontinued. Of note, cyclosporine has been shown to have anti-coronavirus activity. 6 There is a case report of NLP treatment with chloroquine phosphate, with improvement noted This article is protected by copyright. All rights reserved. after 10 weeks, and complete remission (20 nails) after 30 weeks. 7 There were no adverse events. Chloroquine and hydroxychloroquine have been shown to inhibit SARS-CoV-2 in vitro, with the latter showing higher efficacy and less toxicity. 8 However, their efficacy for COVID-19 treatment remains an area of active investigation. Completed trials have shown mixed results and varying degrees of bias with poor study design. 9 NLP is a true nail emergency and may lead to permanent debilitating nail loss. Thus, treatment must be aggressive and individualized. Careful pharmacologic selection is mandatory during this pandemic and collection of specific COVID-19 data is warranted to establish evidence-based guidelines. Abbreviations: NLP -nail lichen planus This article is protected by copyright. All rights reserved. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic Nail lichen planus: A true nail emergency Isolated nail lichen planus: An expert consensus on treatment of the classical form Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Therapeutics for Adult Nail Psoriasis and Nail Lichen Planus: A Guide for Clinicians The SARS-coronavirus-host interactome: identification of cyclophilins as target for pancoronavirus inhibitors Lichen planus of the nail: treatment with antimalarials Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19 This article is protected by copyright. All rights reserved.